The potential benefit of allogeneic over autologous transplantation in patients with very early relapsed and refractory follicular lymphoma with prior remission duration of ≤12 months

British Journal of Haematology

Volumn 173, Issue 2, 2016, Pages 260-264

  Lunning, Matthew A ^a   Migliacci, Jocelyn C ^b   Hilden, Patrick ^b   Devlin, Sean M ^b   Castro Malaspina, Hugo ^b,c   Giralt, Sergio ^b,c   Perales, Miguel Angel ^b,c   Zelenetz, Andrew D ^b,c   Moskowitz, Craig H ^b,c   Sauter, Craig S ^b,c  

^a UNIVERSITY OF NEBRASKA AT OMAHA   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^c WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

Follicular lymphoma; Non Hodgkin lymphoma; Stem cell transplantation

Indexed keywords

RITUXIMAB;

ADULT; AGED; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER PROGNOSIS; CLINICAL ARTICLE; CLINICAL EFFECTIVENESS; CLINICAL FEATURE; CONTROLLED STUDY; EVENT FREE SURVIVAL; FEMALE; FOLLICULAR LYMPHOMA; HUMAN; INTERMETHOD COMPARISON; MALE; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; RELAPSE; REMISSION; RETROSPECTIVE STUDY; ALLOTRANSPLANTATION; AUTOTRANSPLANTATION; CHRONIC DISEASE; FOLLOW UP; HEMATOPOIETIC STEM CELL TRANSPLANTATION; LYMPHOMA, FOLLICULAR; MIDDLE AGED; MORTALITY; PROCEDURES; TREATMENT OUTCOME; TUMOR RECURRENCE;

ADULT; AGED; CHRONIC DISEASE; FOLLOW-UP STUDIES; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LYMPHOMA, FOLLICULAR; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; REMISSION INDUCTION; TRANSPLANTATION, AUTOLOGOUS; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME;

EID: 84957676400     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/bjh.13947     Document Type: Article

References (15)

1. Avivi, I., Montoto, S., Canals, C., Maertens, J., Al-Ali, H., Mufti, G.J., Finke, J., Schattenberg, A., Fanin, R., Cornelissen, J.J., Vernant, J.P., Russell, N., Beguin, Y., Thomson, K., Verdonck, L.F., Kobbe, G., Tilly, H., Socie, G. & Sureda, A. (2009) Matched unrelated donor stem cell transplant in 131 patients with follicular lymphoma: an analysis from the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. British Journal of Haematology, 147, 719-728.
2. Casulo, C., Byrtek, M., Dawson, K.L., Zhou, X., Farber, C.M., Flowers, C.R., Hainsworth, J.D., Maurer, M.J., Cerhan, J.R., Link, B.K., Zelenetz, A.D. & Friedberg, J.W. (2015) Early relapse of follicular lymphoma after rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone defines patients at high risk for death: an analysis from the National lymphocare study. Journal of Clinical Oncology, 33, 2516-2522.
3. Cheson, B.D., Horning, S.J., Coiffier, B., Shipp, M.A., Fisher, R.I., Connors, J.M., Lister, T.A., Vose, J., Grillo-Lopez, A., Hagenbeek, A., Cabanillas, F., Klippensten, D., Hiddemann, W., Castellino, R., Harris, N.L., Armitage, J.O., Carter, W., Hoppe, R. & Canellos, G.P. (1999) Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. Journal of Clinical Oncology, 17, 1244.
4. Cheson, B.D., Pfistner, B., Juweid, M.E., Gascoyne, R.D., Specht, L., Horning, S.J., Coiffier, B., Fisher, R.I., Hagenbeek, A., Zucca, E., Rosen, S.T., Stroobants, S., Lister, T.A., Hoppe, R.T., Dreyling, M., Tobinai, K., Vose, J.M., Connors, J.M., Federico, M. & Diehl, V. (2007) Revised response criteria for malignant lymphoma. Journal of Clinical Oncology, 25, 579-586.
5. Evens, A.M., Vanderplas, A., LaCasce, A.S., Crosby, A.L., Nademanee, A.P., Kaminski, M.S., Abel, G.A., Millenson, M., Czuczman, M.S., Rodriguez, M.A., Niland, J., Zelenetz, A.D., Gordon, L.I. & Friedberg, J.W. (2013) Stem cell transplantation for follicular lymphoma relapsed/refractory after prior rituximab: a comprehensive analysis from the NCCN lymphoma outcomes project. Cancer, 119, 3662-3671.
6. Hiddemann, W., Kneba, M., Dreyling, M., Schmitz, N., Lengfelder, E., Schmits, R., Reiser, M., Metzner, B., Harder, H., Hegewisch-Becker, S., Fischer, T., Kropff, M., Reis, H.E., Freund, M., Wormann, B., Fuchs, R., Planker, M., Schimke, J., Eimermacher, H., Trumper, L., Aldaoud, A., Parwaresch, R. & Unterhalt, M. (2005) Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood, 106, 3725-3732.
7. Khouri, I.F., McLaughlin, P., Saliba, R.M., Hosing, C., Korbling, M., Lee, M.S., Medeiros, L.J., Fayad, L., Samaniego, F., Alousi, A., Anderlini, P., Couriel, D., de Lima, M., Giralt, S., Neelapu, S.S., Ueno, N.T., Samuels, B.I., Hagemeister, F., Kwak, L.W. & Champlin, R.E. (2008) Eight-year experience with allogeneic stem cell transplantation for relapsed follicular lymphoma after nonmyeloablative conditioning with fludarabine, cyclophosphamide, and rituximab. Blood, 111, 5530-5536.
8. Klyuchnikov, E., Bacher, U., Kroger, N.M., Hari, P.N., Ahn, K.W., Carreras, J., Bachanova, V., Bashey, A., Cohen, J.B., D'Souza, A., Freytes, C.O., Gale, R.P., Ganguly, S., Hertzberg, M.S., Holmberg, L.A., Kharfan-Dabaja, M.A., Klein, A., Ku, G.H., Laport, G.G., Lazarus, H.M., Miller, A.M., Mussetti, A., Olsson, R.F., Slavin, S., Usmani, S.Z., Vij, R., Wood, W.A., Maloney, D.G., Sureda, A.M., Smith, S.M. & Hamadani, M. (2015) Reduced-Intensity allografting as first transplantation approach in relapsed/refractory grades one and two follicular lymphoma provides improved outcomes in long-term survivors. Biology of Blood and Marrow Transplantation, 21, 2091-2099.
9. Kornacker, M., Stumm, J., Pott, C., Dietrich, S., Sussmilch, S., Hensel, M., Nickelsen, M., Witzens-Harig, M., Kneba, M., Schmitz, N., Ho, A.D. & Dreger, P. (2009) Characteristics of relapse after autologous stem-cell transplantation for follicular lymphoma: a long-term follow-up. Annals of Oncology, 20, 722-728.
10. Reddy, N., Greer, J.P., Goodman, S., Engelhardt, B., Oluwole, O., Jagasia, M.H. & Savani, B.N. (2012) Long-term outcome after autologous or allogeneic stem cell transplantation in patients with recurrent follicular lymphoma. Bone Marrow Transplantation, 47, 1318-1320.
11. Robinson, S.P., Canals, C., Luang, J.J., Tilly, H., Crawley, C., Cahn, J.Y., Pohlreich, D., Le Gouill, S., Gilleece, M., Milpied, N., Attal, M., Biron, P., Maury, S., Rambaldi, A., Maertens, J., Capria, S., Colombat, P., Montoto, S. & Sureda, A. (2013) The outcome of reduced intensity allogeneic stem cell transplantation and autologous stem cell transplantation when performed as a first transplant strategy in relapsed follicular lymphoma: an analysis from the Lymphoma Working Party of the EBMT. Bone Marrow Transplantation, 48, 1409-1414.
12. Sauter, C.S., Barker, J.N., Lechner, L., Zheng, J., Devlin, S.M., Papadopoulos, E.B., Perales, M.A., Jakubowski, A.A., Goldberg, J.D., Koehne, G., Ceberio, I., Giralt, S., Zelenetz, A.D., Moskowitz, C.H. & Castro-Malaspina, H. (2014a). A Phase II study of a nonmyeloablative allogeneic stem cell transplant with peritransplant rituximab in patients with B cell lymphoid malignancies: favorably durable event-free survival in chemosensitive patients. Biol Blood Marrow Transplant. 2014;20:354-60.
13. Sauter, C.S., Lechner, L., Scordo, M., Zheng, J., Devlin, S.M., Fleming, S.E., Castro-Malaspina, H. & Moskowitz, C.H. (2014b) Pretransplantation fluorine-18-deoxyglucose-positron emission tomography scan lacks prognostic value in chemosensitive B cell non-hodgkin lymphoma patients undergoing nonmyeloablative allogeneic stem cell transplantation. Biology of Blood and Marrow Transplantation, 20, 881-884.
14. Schouten, H.C., Qian, W., Kvaloy, S., Porcellini, A., Hagberg, H., Johnson, H.E., Doorduijn, J.K., Sydes, M.R. & Kvalheim, G. (2003) High-dose therapy improves progression-free survival and survival in relapsed follicular non-Hodgkin's lymphoma: results from the randomized European CUP trial. Journal of Clinical Oncology, 21, 3918-3927.
15. Tomblyn, M.R., Ewell, M., Bredeson, C., Kahl, B.S., Goodman, S.A., Horowitz, M.M., Vose, J.M., Negrin, R.S. & Laport, G.G. (2011) Autologous versus reduced-intensity allogeneic hematopoietic cell transplantation for patients with chemosensitive follicular non-hodgkin lymphoma beyond first complete response or first partial response. Biology of Blood and Marrow Transplantation, 17, 1051-1057.